Carisma Therapeutics, Inc.
CARM
$0.06
$0.019.62%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -91.87% | -73.53% | |||
| Gross Profit | 1,958.62% | 55.33% | |||
| SG&A Expenses | -63.06% | -14.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -75.15% | -55.77% | |||
| Operating Income | 858.29% | 38.10% | |||
| Income Before Tax | 557.51% | -5.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 557.51% | -5.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 557.51% | -5.48% | |||
| EBIT | 858.29% | 38.10% | |||
| EBITDA | 858.29% | 33.38% | |||
| EPS Basic | 557.50% | -5.46% | |||
| Normalized Basic EPS | 936.27% | 42.71% | |||
| EPS Diluted | 555.84% | -5.46% | |||
| Normalized Diluted EPS | 933.25% | 42.71% | |||
| Average Basic Shares Outstanding | 0.00% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||